Valuation: Amarin Corporation plc

Market Cap 239M 213M 197M 179M 338M 22.69B 344M 2.37B 928M 11.84B 897M 878M 37.75B P/E 2026 *
-162x
P/E 2027 * -189x
Enterprise Value 76.83M 68.3M 63.3M 57.59M 109M 7.29B 110M 761M 298M 3.81B 288M 282M 12.13B EV / Sales 2026 *
0.43x
EV / Sales 2027 * 0.36x
Free-Float
86.93%
Yield 2026 *
-
Yield 2027 * -
1 day-2.16%
1 week-5.90%
Current month-12.92%
1 month-18.39%
3 months-18.79%
6 months-24.43%
Current year-18.88%
1 week 11.25
Extreme 11.25
11.93
1 month 11.25
Extreme 11.25
13.9
Current year 11.25
Extreme 11.25
17.31
1 year 11.25
Extreme 11.25
20.9
3 years 7.08
Extreme 7.08
27.4
5 years 7.08
Extreme 7.08
102.2
10 years 7.08
Extreme 7.08
522.4
Manager TitleAgeSince
Chief Executive Officer 63 03/06/2024
Director of Finance/CFO 42 22/10/2024
Compliance Officer 56 14/11/2023
Director TitleAgeSince
Director/Board Member 63 03/06/2024
Director/Board Member 43 27/02/2023
Director/Board Member 67 27/02/2023
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Exercice

Chief Financial Officer

781 0.0002%
01/07/26 Exercice

Chief Operating Officer

9,302 0.0022%
01/07/26 Exercice

Chief Technology Officer

9,263 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
-2.16%-5.90%-42.36%-28.81% 239M
-6.60%-8.56%+49.38%+63.51% 65B
-4.09%-0.11%+2.22%+53.15% 51.19B
+0.03%+5.56%+9.10%+69.05% 51.2B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-2.76%-9.54%-16.58%-9.19% 22.03B
Average -1.88%-2.09%+33.13%+80.09% 37.21B
Weighted average by Cap. -2.30%-1.21%+42.09%+95.43%

Financials

2026 *2027 *
Net sales 177M 158M 146M 133M 251M 16.84B 255M 1.76B 689M 8.79B 666M 652M 28.02B 177M 157M 146M 133M 250M 16.78B 254M 1.75B 687M 8.76B 664M 650M 27.92B
Net income -26.62M -23.67M -21.94M -19.96M -37.66M -2.53B -38.26M -264M -103M -1.32B -99.92M -97.79M -4.2B -18.32M -16.28M -15.09M -13.73M -25.91M -1.74B -26.33M -181M -71.13M -907M -68.75M -67.29M -2.89B
Net Debt -162M -144M -134M -122M -230M -15.4B -233M -1.61B -630M -8.04B -609M -596M -25.62B -175M -155M -144M -131M -247M -16.6B -251M -1.73B -679M -8.66B -656M -642M -27.61B
Projected Income Statement - Annual - Amarin Corporation plc
Logo Amarin Corporation plc
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Employees
80
Date Price Change Volume
16/10/26 US$11.32 -2.16% 113,657
15/10/26 US$11.57 -0.34% 54,357
14/10/26 US$11.61 +0.26% 51,010
13/10/26 US$11.58 +0.43% 102,387
12/10/26 US$11.53 -4.16% 90,041
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Amarin Corporation plc
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
11.32USD
Average target price
12.50USD
Spread / Average Target
+10.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amarin Corporation plc
  1. Stock Market
  2. Stocks
  3. AMRN Stock